Grade 3 Meningioma — Trials

Grade 3 Meningioma — Trials · CancerIndex

Clinical trials

Registered studies

41 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 10%
Top sponsor: Emory University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (8)

clinicaltrialsPublishedShowing 1–12 of 12 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02847559	Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma	completed	Phase 2	20	Northwestern UniversityOTHER	1	Sep 9, 2026	clinicaltrials
NCT03604978	Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma	active not recruiting	Phase 1 / Phase 2	38	National Cancer Institute (NCI)NIH	1	Jul 31, 2026